President Donald Trump’s recently announced agreements with pharmaceutical companies are expected to have a limited effect on what most Americans pay for prescription drugs, according to health policy experts who say the scope and structure of the deals leave many patients unaffected. Since Sept. 30, the Trump administration has reached agreements with 14 drugmakers in exchange for relie
President Donald Trump’s recently announced agreements with pharmaceutical companies are expected to have a limited effect on what most Americans pay for prescription drugs, according to health policy experts who say the scope and structure of the deals leave many patients unaffected. Since Sept. 30, the Trump administration has reached agreements with 14 drugmakers in exchange for relie